Using NeuroBiofeedback to Improve Brain Function in Multiple Sclerosis Patients
Study of Brain Activations and Physiological Responses Using NeuroBiofeedback in Patients With Multiple Sclerosis.Study of Brain Activations and Physiological Responses Using NeuroBiofeedback in Patients With Multiple Sclerosis
NA · IRCCS Centro Neurolesi Bonino Pulejo · NCT06239090
This study is testing if NeuroBiofeedback training can help people with Multiple Sclerosis improve their thinking skills and mood.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 44 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | IRCCS Centro Neurolesi Bonino Pulejo (other) |
| Locations | 1 site (Messina) |
| Trial ID | NCT06239090 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of NeuroBiofeedback (NBF) training in patients with Multiple Sclerosis (MS) to enhance cognitive processes and mood regulation. Participants will engage in cognitive tasks while their brain activity and physiological responses are monitored. The study aims to assess how NBF can modulate cortical activity and improve attentional processes, potentially reducing anxiety. The research will involve patients aged 18-65 with a confirmed MS diagnosis and stable clinical status, who will undergo assessments without experimental procedures.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-65 with a confirmed diagnosis of Multiple Sclerosis and a MoCA score of 20 or higher.
Not a fit: Patients with severe psychotic symptoms, epilepsy, or multiple pathologies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved cognitive function and mood regulation in patients with Multiple Sclerosis.
How similar studies have performed: Previous studies have shown promising results for NeuroBiofeedback in treating neurological disorders, but this specific application in MS is less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18-65 years ; * Confirmed clinical diagnosis; * Written informed consent obtained from the patient; * Moca score ≥ 20; * Patients with no contraindications to perform MRI and EEG. * Clinical stability * documented absence of relapse in the last month before treatment Exclusion Criteria: * Ascertained diagnosis of multiple pathologies, * Patients with severe psychotic symptoms; * Epilepsy; * Drug use; * Endocrine-metabolic encephalopathies. * Presence of multiple therapies
Where this trial is running
Messina
- IRCCS Centro Neurolesi Bonino Pulejo — Messina, Italy (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Sclerosis, Mood Disorders, Cognitive Impairment